155 related articles for article (PubMed ID: 18333865)
1. The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.
Abel S; Russell D; Whitlock LA; Ridgway CE; Muirhead GJ
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):47-53. PubMed ID: 18333865
[TBL] [Abstract][Full Text] [Related]
2. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
Abel S; Russell D; Taylor-Worth RJ; Ridgway CE; Muirhead GJ
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):27-37. PubMed ID: 18333863
[TBL] [Abstract][Full Text] [Related]
3. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
Abel S; Jenkins TM; Whitlock LA; Ridgway CE; Muirhead GJ
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):38-46. PubMed ID: 18333864
[TBL] [Abstract][Full Text] [Related]
4. A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects.
Pozniak AL; Boffito M; Russell D; Ridgway CE; Muirhead GJ
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):54-9. PubMed ID: 18333866
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers.
Abel S; van der Ryst E; Rosario MC; Ridgway CE; Medhurst CG; Taylor-Worth RJ; Muirhead GJ
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):5-18. PubMed ID: 18333861
[TBL] [Abstract][Full Text] [Related]
6. Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers.
Abel S; Russell D; Whitlock LA; Ridgway CE; Muirhead GJ
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):19-26. PubMed ID: 18333862
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects.
Abel S; Russell D; Whitlock LA; Ridgway CE; Nedderman AN; Walker DK
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):60-7. PubMed ID: 18333867
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir.
Andrews E; Glue P; Fang J; Crownover P; Tressler R; Damle B
Br J Clin Pharmacol; 2010 Jan; 69(1):51-7. PubMed ID: 20078612
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
Kiser JJ; Fletcher CV; Flynn PM; Cunningham CK; Wilson CM; Kapogiannis BG; Major-Wilson H; Viani RM; Liu NX; Muenz LR; Harris DR; Havens PL;
Antimicrob Agents Chemother; 2008 Feb; 52(2):631-7. PubMed ID: 18025112
[TBL] [Abstract][Full Text] [Related]
10. A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects.
Chan PL; Weatherley B; McFadyen L
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):76-85. PubMed ID: 18333869
[TBL] [Abstract][Full Text] [Related]
11. CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study.
Garvey L; Nelson M; Latch N; Erlwein OW; Allsop JM; Mitchell A; Kaye S; Watson V; Back D; Taylor-Robinson SD; Winston A
J Antimicrob Chemother; 2012 Jan; 67(1):206-12. PubMed ID: 21987241
[TBL] [Abstract][Full Text] [Related]
12. Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects.
Davis JD; Hackman F; Layton G; Higgins T; Sudworth D; Weissgerber G
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):68-75. PubMed ID: 18333868
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
Vourvahis M; Fang J; Checchio T; Milton A; Weatherley B; McFadyen L; Heera J
HIV Clin Trials; 2013; 14(3):99-109. PubMed ID: 23835512
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment.
Abel S; Davis JD; Ridgway CE; Hamlin JC; Vourvahis M
Antivir Ther; 2009; 14(6):831-7. PubMed ID: 19812445
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients.
Rosario MC; Jacqmin P; Dorr P; James I; Jenkins TM; Abel S; van der Ryst E
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):86-94. PubMed ID: 18333870
[TBL] [Abstract][Full Text] [Related]
16. HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.
Veselinovic M; Yang KH; LeCureux J; Sykes C; Remling-Mulder L; Kashuba ADM; Akkina R
Virology; 2014 Sep; 464-465():253-263. PubMed ID: 25105490
[TBL] [Abstract][Full Text] [Related]
17. Maraviroc: pharmacokinetics and drug interactions.
Abel S; Back DJ; Vourvahis M
Antivir Ther; 2009; 14(5):607-18. PubMed ID: 19704163
[TBL] [Abstract][Full Text] [Related]
18. Models for predicting effective HIV chemoprevention in women.
Nicol MR; Emerson CW; Prince HM; Nelson JA; Fedoriw Y; Sykes C; Geller EJ; Patterson KB; Cohen MS; Kashuba AD
J Acquir Immune Defic Syndr; 2015 Apr; 68(4):369-76. PubMed ID: 25501616
[TBL] [Abstract][Full Text] [Related]
19. From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework.
Fang J; Jadhav PR
J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):357-68. PubMed ID: 22736302
[TBL] [Abstract][Full Text] [Related]
20. Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.
Mills A; Mildvan D; Podzamczer D; Fätkenheuer G; Leal M; Than S; Valluri SR; Craig C; McFadyen L; Vourvahis M; Heera J; Valdez H; Rinehart AR; Portsmouth S
J Acquir Immune Defic Syndr; 2013 Feb; 62(2):164-70. PubMed ID: 23187936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
